



ESUR19

26th Meeting of the EAU Section of Urological Research

In collaboration with the Society for Basic Urologic Research (SBUR) and the EAU Section of Uro-pathology (ESUP)

10-12 October 2019, Porto, Portugal

www.esur19.org



Scientific Programme

Thursday, 10 October 2019

10.00 Registration opens

12.00 – 14.00 **ESU Course**
New challenges and unmet needs in basic science and histopathology to address the clinical management of renal malignancies
Chair: M. Hora, Plzen (CZ)

12.00 – 12.05 **European School of Urology: A unique possibility for urological education**
M. Hora, Plzen (CZ)

12.05 – 12.30 **Current indications and challenges for the treatment of renal cell carcinoma according to the EAU guidelines**
1. Therapeutic options in localized disease (surgery, ablative techniques, active surveillance); 2. Systemic treatment in metastatic disease
M. Hora, Plzen (CZ)

12.30 – 13.30 **Histopathological classification and molecular pathology of renal cell tumors: basics and clinical value for decision making**
1. Histopathological and molecular characterization of renal cell carcinoma
A. Hartmann, Erlangen (DE)
2. Incorporation of genetic and molecular profiling into clinical decision-making in patients with kidney cancer: Ready for prime time?
R. Leao, Coimbra (PT)

13.30 – 14.00 **Discussion and close**

Aims and objectives

The aim of this ESU course is to describe the current indications for the treatment of renal malignancies and to provide an update on the histopathological features and molecular patterns of kidney cancer. The course will also focus on the opportunities for the introduction of genetic and molecular profiling in the daily clinical practice of patients with renal cell carcinoma.

14.30 – 14.45 **Opening**
Carmen Jeronimo, Porto (PT) Meeting Chair
Kerstin Junker, Homburg (DE) ESUR Chair
Rodolfo Montironi, Ancona (IT) ESUP Chair
Rui Henrique, Porto (PT) Director IPO Porto

14.45 – 16.10 **Session 1**
Microenvironment, metabolism and epigenetic reprogramming
Chairs: Guido Jenster, Rotterdam (NL)
Gabri van der Pluijm, Leiden (NL)

14.45 – 15.10 **Phenotype-independent DNA methylation changes in prostate cancer**
Norman Maitland, York (GB)

- 15.10 – 15.30 **The tumour-microenvironment as a barrier or enabler of the host immune response**
Gabriel Malouf, Strasbourg (FR)
- 15.30 – 15.50 **MicroRNA expression and activity in the prostate cancer tumour microenvironment**
Shawn Lupold, Baltimore US
- 15.50 – 16.10 **The multifunctional role of the enzyme APE1/Ref-1 in bladder cancer: Growth, cell survival and muscle invasion**
Travis Jerde, Indianapolis (US)
- 16.10 - 16.40 **Break**
- 16.40 – 17.40 **Session 2**
Translational research in bladder dysfunction
Chairs: Francisco Cruz, Porto (PT)
Alexandra Masson-Lecomte, Paris (FR)
Elena Martens-Uzunova, Rotterdam (NL)
- 16.40 – 17.00 **RNA profiling in bladder pathologies**
Katia Monastyrskaya, Berne (CH)
- 17.00 – 17.20 **Neurotrophins and stress in bladder pain**
Ana Charrua, Porto (PT)
- 17.20 – 17.40 **Regulating axonal growth for spinal cord regeneration**
Martin Schwab, Zurich (CH)
- 17.40 – 18.30 **Short presentations 1**
Chairs: Francisco Cruz, Porto (PT)
Alexandra Masson-Lecomte, Paris (FR)
Elena Martens-Uzunova, Rotterdam (NL)
- 17.40 – 17.50 **01 Study on the possible interactions between FGFR1- and AR-regulated mechanisms in prostate cancer**
Syeda Afshan, Turku (FI)
- 17.50 – 18.00 **02 Mechanisms of ETS family transcription factors that promote prostate cancer**
Peter Hollenhorst, Bloomington (US)
- 18.00 – 18.10 **03 Mitochondrial complex I gene mutations drive metabolic reprogramming in prostate cancer**
Helmut Klocker, Innsbruck (AT)
- 18.10 – 18.20 **04 Metabolic reprogramming and epigenetic landscape: an interplay to renal cell carcinoma aggressiveness promotion**
Vera Miranda-Gonçalves, Porto (PT)
- 18.20 – 18.30 **05 The adipose tissue that surrounds the prostate gland exhibits traits of hypoxic state that could contribute to its role in prostate cancer progression**
Mathieu Roumiguie, Toulouse (FR)

Friday, 11 October 2019

08.30 – 09.40

Session 3

Epidrugs: From basics to clinical trials

*Chairs: Jocelyn Ceraline, Strasbourg (FR)
Carmen Jeronimo, Porto (PT)
Antonia Vlahou, Athens (GR)*

08.30 – 08.50

Novel approaches to targeting the androgen receptor in CRPC

Ganesh Raj, Dallas (US)

08.50 – 09.15

Clinical trials on epigenetic therapies for urological tumours

Simon Crabb, Southampton (GB)

09.15 – 09.40

Epidrugs designing

Paola Arimondo, Paris (FR)

09.40 – 10.20

Session 4

Immuno-oncology: pre-clinical and clinical trials: Pre-clinical studies

*Chairs: Jocelyn Ceraline, Strasbourg (FR)
Carmen Jeronimo, Porto (PT)
Antonia Vlahou, Athens (GR)*

09.40 – 10.00

Inhibition of a G9a/EZH2 network triggers an immune-mediated bladder cancer regression

Jesus Paramio, Madrid (ES)

10.00 – 10.20

Oncolytic viruses as a kick-start for immunotherapy

Gabri van der Pluijm, Leiden (NL)

10.20 – 10.50

Break

10.50 – 11.50

Session 5

Immuno-oncology: Pre-clinical and clinical trials: Clinical trials

*Chairs: Imran Ahmad, Glasgow (GB)
Allen Gao, Sacramento (US)
Mariangela Mancini, Padua (IT)*

10.50 – 11.10

Mechanisms of action and resistance to BCG immunotherapy: New developments

Joost Boormans, Rotterdam (NL)

11.10 – 11.30

Immunotherapy combinations and sequences in urothelial cancer: Facts and hopes

Yohann Lorient, Villejuif (FR)

11.30 – 11.50

New combination partners of IO (eg. anti-angiogenesis) in RCC (preclinical concept and recent clinical studies)

Andreas Pircher, Innsbruck (AT)

11.50 – 12.30

Short presentations 2

*Chairs: Imran Ahmad, Glasgow (GB)
Allen Gao, Sacramento (US)
Mariangela Mancini, Padua (IT)*

11.50 – 12.00

06 *Artesunate reduces cell growth and induces ferroptosis in therapy-resistant renal cell carcinoma cells*

Eva Juengel, Mainz (DE)

12.00 – 12.10

07 *225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts*

Egbert Oosterwijk, Nijmegen (NL)

12.10 – 12.20	08	<i>Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22</i> Esteban Abella, San Leandro (US)
12.20 – 12.30	09	<i>Preliminary proteomic analysis of F.F.P.E. tumor samples for predicting the response of bladder cancer patients to anti-P.D.-1/P.D.L.-1 therapy</i> Rafael Strogilos, Athens (GR)
12.30 – 13.30		Lunch
13.30 – 15.00		Poster session 1 Poster numbers P1 – P40
14.45 – 15.00		Break
15.00 – 16.30		Session 6 Panel session: Local therapy in metastatic prostate cancer <i>Chairs: Isabel Heidegger, Innsbruck (AT)</i> <i>Hing Leung, Glasgow (GB)</i>
15.00 – 15.15		Radiotherapy To be confirmed
15.15 – 15.30		Surgery Matthias Saar, Homburg (DE)
15.30 -15.45		Hormonal therapy Igor Tsaour, Mainz (DE)
15.45 – 16.05		Role of primary tumour for metastasis development and therapy response (including exosomes) Bruno Costa-Silva, Lisbon (PT)
16.05 – 16.30		Panel discussion
16.30 – 17.30		Short presentations 3 <i>Chairs: Egbert Oosterwijk, Nijmegen (NL)</i> <i>Martin Puhr, Innsbruck (AT)</i>
16.30 – 16.50		Role of prostate derived Ets factor in prostate cancer Hari Koul, Shreveport (US)
16.50 – 17.00	010	<i>A transcription factor activity profile as a prognostic signature for androgen deprivation therapy resistance predisposition in prostate cancer patients</i> Mario Cangiano, Leiden (NL)
17.00 – 17.10	011	<i>Cytoreductive primary tumor removal slows down disease progression in an orthotopic xenograft model of prostate cancer</i> Johannes Linxweiler, Homburg (DE)
17.10 – 17.20	012	<i>Tumor-secreted exosomal miR-424: impact on prostate tumorigenesis in mouse models and patients</i> Giuseppina Carbone, Bellinzona (CH)
17.20 – 17.30	013	<i>A duplex quantitative real-time PCR assay for the detection of small non-coding RNA in urinary extracellular vesicles</i> Elena Martens-Uzunova, Rotterdam (NL)

Saturday, 12 October 2019

08.45 – 09.50

Session 7

Molecular subtypes and therapeutics

Chairs: Kerstin Junker, Homburg (DE)
Holger Moch, Zurich (CH)
Rodolfo Montironi, Ancona (IT)

08.45 – 09.10

Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal
Scott Shepherd, London (GB)

09.10 – 09.30

Histopathological subtypes in RCC: consequences for systemic therapy
Holger Moch, Zurich (CH)

09.30 – 09.50

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
David Wedge, Oxford (GB)

09.50 – 10.30

Short presentations 4

Chairs: Kerstin Junker, Homburg (DE)
Holger Moch, Zurich (CH)
Rodolfo Montironi, Ancona (IT)

09.50 – 10.00

014 Urothelial bladder cancer risk patterns according to tumor taxonomic subtypes
Raquel Benitez Dorta, Madrid (ES)

10.00 – 10.10

015 Immune infiltrate, immune checkpoints and mismatch repair proteins in testicular germ cell tumors: A role in prognosis and patient outcome
Joao Lobo, Porto (PT)

10.10 – 10.20

016 Immunogenomic analysis reveals that tumor aggressiveness is associated with a decreased CD8 T cell signature in an in vivo prostate cancer model
Merle Van Gelder, Rotterdam (NL)

10.20 – 10.30

017 The mTOR kinase directly regulates FBP1 gene expression via interaction with SWI/SNF chromatin remodeling complex in clear cell renal cell carcinoma (ccRCC)
Elzbieta Sarnowska, Warsaw (PL)

10.30 – 11.00

Break

11.00 – 11.30

Session 8

Data protection regulation and ethics

Chairs: Yves Allory, Paris (FR)
Natasha Kyprianou, New York (US)

11.00 – 11.30

Open consent, biobanking and data protection law: Can open consent be ‘informed’ under the data protection regulation?
Dara Hallinan, Karlsruhe (DE)

11.30 – 12.30

Short presentations 5

Chairs: Yves Allory, Paris (FR)
Natasha Kyprianou, New York (US)

11.30 – 11.40

018 A novel calcium-mediated epithelial-to-mesenchymal transition pathway controlled by lipids: an opportunity for prostate cancer adjuvant therapy
Fanny Bery, Tours (FR)

11.40 – 11.50

019 Biomarker exploration of extracellular vesicles in renal cell carcinoma
Dirk Himbert, Homburg (DE)

11.50 – 12.00

020 m6A-regulated long non-coding RNAs in prostate cancer
Daniela Barros Silva, Porto (PT)

12.00 – 12.10

021 Macrophage-associated changes in peri-prostatic adipose tissue; a novel local driver of prostate tumorigenesis?
Laura Martinez Campesino, Sheffield (GB)

12.10 – 12.20	O22 <i>Comprehensive multi-omic profiling of tumor endothelial cells of prostate tissue</i> Andreas Pircher, Innsbruck (AT)
12.20 – 12.30	O23 <i>Effects of systemic glucocorticoid administration on stromal and epithelial GR signalling with consequences for prostate cancer progression</i> Martin Pühr, Innsbruck (AT)
12.30 – 13.30	Lunch
13.30 – 15.00	Poster session 2 Poster numbers P41 – P76 and LB1 – LB7
14.45 – 15.00	Break
15.00 – 15.30	Dominique Chopin Award <i>Presented by Kerstin Junker, Homburg (DE)</i>
	Dominique Chopin Lecture Is there still room for improvement in the clinical targeting of the androgen receptor: A molecular study Frank Claessens, Leuven (BE)
15.30 – 16.00	ARTP Award and closing remarks